| Center For Better Hearing, Llc | |
|
160 West St, Bldg 1, Suite B, Cromwell, CT 06416-2441 | |
| (860) 632-5003 | |
| (860) 632-5532 |
| Full Name | Center For Better Hearing, Llc |
|---|---|
| Type | Facility |
| Speciality | Audiologist |
| Location | 160 West St, Cromwell, Connecticut |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861604506 | NPI | - | NPPES |
| 3058249 | Other | CT | AETNA |
| 730000192CT01 | Other | CT | ANTHEM |
| 206715 | Other | CT | WELLCARE |
| 4067674 | Medicaid | CT | |
| 11092 | Other | CT | CTCARE |
| 7586386 | Other | CT | AETNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 231H00000X | Audiologist | 192 (Connecticut) | Primary |
| 237600000X | Audiologist-hearing Aid Fitter | 192 (Connecticut) | Secondary |
| Provider Name | Ann Mcmahon |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1326199670 PECOS PAC ID: 1850563149 Enrollment ID: I20111010000564 |
News Archive
The cell is understood to be highly organized, with specialized areas for different functions and molecular motors shuttling components around.
A rare, inherited neurodegenerative disorder will soon be the focus of an international clinical research effort led by Houston Methodist and funded by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health.
Hospital for Special Care announced today the launch of the region's first Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Unit at its Neuromuscular Center. The new unit will be headed by Jinsy A. Andrews, M.D., a physician researcher recruited from Columbia University. Dr. Andrews, Director of Research & Clinical Trials Unit, Hospital for Special Care, specializes in neuromuscular research and will facilitate the hospital's first clinical trial for ALS upon her arrival.
Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.
Dozens of suits against drug companies have been dismissed in federal and state courts because of a decision by the Supreme Court last year that makes it virtually impossible to sue generic manufacturers for failing to provide adequate warning of a prescription drug's dangers. This outrageous denial of a patient's right to recover fair damages makes it imperative that Congress or the Food and Drug Administration fashion a remedy.
› Verified 7 days ago
| Provider Name | Megan Marie Blanchette |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1194030478 PECOS PAC ID: 0840462149 Enrollment ID: I20111010000574 |
News Archive
The cell is understood to be highly organized, with specialized areas for different functions and molecular motors shuttling components around.
A rare, inherited neurodegenerative disorder will soon be the focus of an international clinical research effort led by Houston Methodist and funded by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health.
Hospital for Special Care announced today the launch of the region's first Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Unit at its Neuromuscular Center. The new unit will be headed by Jinsy A. Andrews, M.D., a physician researcher recruited from Columbia University. Dr. Andrews, Director of Research & Clinical Trials Unit, Hospital for Special Care, specializes in neuromuscular research and will facilitate the hospital's first clinical trial for ALS upon her arrival.
Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.
Dozens of suits against drug companies have been dismissed in federal and state courts because of a decision by the Supreme Court last year that makes it virtually impossible to sue generic manufacturers for failing to provide adequate warning of a prescription drug's dangers. This outrageous denial of a patient's right to recover fair damages makes it imperative that Congress or the Food and Drug Administration fashion a remedy.
› Verified 7 days ago
| Provider Name | Sarah Proulx |
|---|---|
| Provider Type | Practitioner - Qualified Audiologist |
| Provider Identifiers | NPI Number: 1083925929 PECOS PAC ID: 6901079052 Enrollment ID: I20111104000477 |
News Archive
The cell is understood to be highly organized, with specialized areas for different functions and molecular motors shuttling components around.
A rare, inherited neurodegenerative disorder will soon be the focus of an international clinical research effort led by Houston Methodist and funded by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health.
Hospital for Special Care announced today the launch of the region's first Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Unit at its Neuromuscular Center. The new unit will be headed by Jinsy A. Andrews, M.D., a physician researcher recruited from Columbia University. Dr. Andrews, Director of Research & Clinical Trials Unit, Hospital for Special Care, specializes in neuromuscular research and will facilitate the hospital's first clinical trial for ALS upon her arrival.
Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.
Dozens of suits against drug companies have been dismissed in federal and state courts because of a decision by the Supreme Court last year that makes it virtually impossible to sue generic manufacturers for failing to provide adequate warning of a prescription drug's dangers. This outrageous denial of a patient's right to recover fair damages makes it imperative that Congress or the Food and Drug Administration fashion a remedy.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Center For Better Hearing, Llc 160 West St, Bldg 1, Suite B, Cromwell, CT 06416-2441 Ph: (860) 632-5003 | Center For Better Hearing, Llc 160 West St, Bldg 1, Suite B, Cromwell, CT 06416-2441 Ph: (860) 632-5003 |
News Archive
The cell is understood to be highly organized, with specialized areas for different functions and molecular motors shuttling components around.
A rare, inherited neurodegenerative disorder will soon be the focus of an international clinical research effort led by Houston Methodist and funded by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health.
Hospital for Special Care announced today the launch of the region's first Amyotrophic Lateral Sclerosis (ALS) Clinical Trials Unit at its Neuromuscular Center. The new unit will be headed by Jinsy A. Andrews, M.D., a physician researcher recruited from Columbia University. Dr. Andrews, Director of Research & Clinical Trials Unit, Hospital for Special Care, specializes in neuromuscular research and will facilitate the hospital's first clinical trial for ALS upon her arrival.
Patients with mild to moderate Alzheimer's disease (AD) who received supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA), believed to possibly reduce the risk of AD, did not experience a reduction in the rate of cognitive and functional decline, compared to patients who received placebo, according to a study in the November 3 issue of JAMA, a theme issue on aging.
Dozens of suits against drug companies have been dismissed in federal and state courts because of a decision by the Supreme Court last year that makes it virtually impossible to sue generic manufacturers for failing to provide adequate warning of a prescription drug's dangers. This outrageous denial of a patient's right to recover fair damages makes it imperative that Congress or the Food and Drug Administration fashion a remedy.
› Verified 7 days ago
Sarah Proulx, AUD Audiologist Medicare: Accepting Medicare Assignments Practice Location: 160 West St, Building 1, Suite B, Cromwell, CT 06416 Phone: 860-632-5003 Fax: 860-632-5532 | |
Mrs. Solange Anderson, CCC-A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 160 West St Bldg 1, Suite B, Cromwell, CT 06416 Phone: 860-632-5003 Fax: 860-632-5532 |